Laura Williams Sells Shares of Ardelyx, Inc.
Ardelyx's Chief Patient Officer sold 31,000 shares on June 18, 2026.
Key Points
- Laura Williams, Chief Patient Officer at Ardelyx, sold 31,000 shares on June 18, 2026, with the stock trading at $6.05.
- Ardelyx has a market cap of $1.49 billion and a forward P/E of 11.75, with a 52-week range from $3.49 to $8.40.
- Ladenburg Thalmann assumed coverage with a 'buy' rating and a $16 target, while the consensus remains a strong buy with a $16.30 average target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Laura Williams, the Chief Patient Officer at Ardelyx, Inc., sold 31,000 shares of the company on June 18, 2026. This transaction was not part of a pre-planned trading arrangement. Shares of Ardelyx, traded on the NasdaqGM under the ticker ARDX, were priced at $6.05 on the day of the sale.
Ardelyx, Inc. Stock Up 67.2%
On Tuesday, Ardelyx's stock was trading near $6.05. The company, which operates in the biotechnology sector, has a market capitalization of about $1.49 billion. Ardelyx's forward P/E ratio stands at 11.75, indicating its projected earnings relative to its current share price. The stock has a beta of 0.576, suggesting it is less volatile than the market. Over the past year, its share price has ranged from $3.49 to $8.40, and it has 50-day and 200-day moving averages of $6.15 and $6.12, respectively.
$ARDX stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Ardelyx, Inc.
In addition to Williams's recent sale, she also conducted another transaction on the same day, selling 81,898 shares at an average price of $5.99 under a pre-planned arrangement. Other notable insider activities include purchases by William Bertrand Jr., Richard Rodgers, and Merdad Parsey, who collectively bought over 100,000 shares on June 16, 2026.
Analysts Set New Price Targets
On June 16, 2026, Ladenburg Thalmann assumed coverage of Ardelyx with a 'buy' rating and a price target of $16. This aligns with the overall strong buy consensus from analysts, who have set an average target price of $16.30. Other firms like HC Wainwright & Co. and Wedbush have maintained 'buy' ratings with targets of $18 and $19, respectively.
About Ardelyx, Inc.
Ardelyx, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on discovering, developing, and commercializing treatments for unmet medical needs. The company offers IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for managing serum phosphorus levels in adults with chronic kidney disease on dialysis. Led by CEO Michael G. Raab, Ardelyx employs 489 people.
Bottom Line
Laura Williams's recent sale of Ardelyx shares highlights ongoing insider activity at the company. Investors often track such transactions as part of their due diligence process. With its stock trading in a volatile range and analysts maintaining a strong buy consensus, Ardelyx remains a company of interest in the biotechnology sector.
Get Ardelyx, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.